Focused Extracorporeal Shockwave Treatment During Early Stage of Osteonecrosis of Femoral Head
Osteonecrosis of the femoral head (ONFH) is a debilitating condition characterized by ischemic lesions in the hip joint, leading to progressive bone degeneration and eventual collapse of the femoral head. Left untreated, it often necessitates total hip replacement, imposing significant financial and physical burdens on patients. In recent years, extracorporeal shockwave therapy (ESWT) has emerged as a promising non-invasive treatment for early-stage ONFH, offering advantages over traditional surgical interventions. This article explores the mechanisms, clinical efficacy, safety, and future directions of focused ESWT (f-ESWT) in managing ONFH.
Pathophysiology and Clinical Challenges of ONFH
ONFH begins as an ischemic event that disrupts blood supply to the femoral head, resulting in osteocyte death and bone marrow edema. Without timely intervention, the structural integrity of the femoral head deteriorates, leading to subchondral fractures, collapse, and secondary osteoarthritis. Early diagnosis and hip-preserving interventions are critical to delaying or avoiding total hip replacement. Traditional treatments, such as core decompression, vascularized bone grafting, and osteotomy, are invasive and associated with variable success rates. In contrast, ESWT presents a non-invasive alternative that stimulates bone and vascular regeneration without surgical risks.
Mechanism of Focused Extracorporeal Shockwave Therapy
ESWT utilizes high-energy acoustic waves generated through electrohydraulic, electromagnetic, or piezoelectric sources. These waves are transmitted through tissues using ultrasonic coupling agents to minimize energy loss. Focused shockwaves differ from radial pressure waves (RPW) by targeting deeper tissues with precise energy concentration, making them suitable for femoral head pathology. The therapeutic effects of f-ESWT occur through four sequential phases:
- Physical Phase: Shockwaves are generated and focused on the necrotic area of the femoral head using parameters optimized to avoid tissue damage.
- Physicochemical Phase: As waves penetrate tissues, they induce mechanical stress, activating cellular signaling pathways.
- Chemical Phase: Local cells secrete cytokines and growth factors, including vascular endothelial growth factor (VEGF), bone morphogenetic protein-2 (BMP-2), and insulin-like growth factor (IGF), which promote angiogenesis and osteogenesis.
- Biological Phase: Enhanced vascularization and bone remodeling reverse ischemic damage, restoring femoral head structure and function.
Key molecular changes include upregulation of pro-angiogenic markers (VEGF, von Willebrand factor, CD31) and osteogenic factors (osteocalcin, alkaline phosphatase), alongside downregulation of inflammatory mediators (intercellular adhesion molecules, Dickkopf-1). These changes collectively enhance bone metabolism and repair.
Clinical Efficacy of ESWT in Early-Stage ONFH
Recent clinical studies and meta-analyses highlight the superiority of ESWT over traditional hip-preserving surgeries. A 2017 meta-analysis by Wang et al. compared ESWT with core decompression, vascularized fibular grafting, and other procedures, concluding that ESWT yielded better functional outcomes and lower complication rates. Clinical trials report significant improvements in pain scores, Harris Hip Scores, and radiographic stabilization of the femoral head in early-stage ONFH patients.
For instance, a 2018 study by Xie et al. demonstrated that high-energy ESWT (energy flux density: 0.47 mJ/mm²) applied via a posterior approach effectively reduced pain and improved hip mobility in 32.4% of patients, with transient side effects such as mild swelling. Another trial by Algarni and Al Moallem (2018) observed radiological evidence of bone regeneration in 75% of patients after six months of ESWT, underscoring its potential to halt disease progression.
Safety and Technical Considerations
ESWT is generally safe, with no reports of severe adverse events such as nerve damage or systemic complications. Minor side effects, including localized erythema, ecchymosis, and transient pain, resolve spontaneously within days. To minimize risks, clinicians use ultrasound guidance to avoid major neurovascular structures and adhere to energy thresholds (≤0.47 mJ/mm²) proven safe in preclinical studies. The posterior approach is preferred to prevent injury to the femoral artery and nerve.
Notably, radial pressure wave therapy (r-ESWT), which generates superficial cavitation effects, is unsuitable for ONFH due to its limited tissue penetration. Focused ESWT remains the gold standard for deep-targeted therapy.
Comparative Advantages Over Surgical Interventions
ESWT offers distinct advantages:
- Non-invasiveness: Avoids surgical risks such as infection, blood loss, and prolonged recovery.
- Cost-effectiveness: Reduces hospitalization expenses and rehabilitation time.
- Repeatability: Can be administered multiple times without cumulative tissue damage.
- Mechanistic versatility: Simultaneously addresses angiogenesis, osteogenesis, and inflammation.
In contrast, core decompression and bone grafting require prolonged rehabilitation and carry risks of graft failure or donor site morbidity.
Future Directions and Research Needs
While existing evidence supports ESWT’s efficacy, large-scale randomized controlled trials (RCTs) are needed to establish standardized protocols for energy settings, treatment frequency, and patient selection. Additionally, mechanistic studies must elucidate long-term molecular changes and optimize shockwave parameters for diverse ONFH subtypes. Multi-center collaborations will enhance the generalizability of findings and facilitate clinical guideline development.
Conclusion
Focused extracorporeal shockwave therapy represents a paradigm shift in managing early-stage ONFH. By harnessing biomechanical and biochemical regenerative mechanisms, ESWT effectively restores femoral head viability while avoiding surgical morbidity. As research progresses, this therapy holds promise for improving quality of life in patients globally, particularly in resource-limited settings where surgical options are inaccessible.
doi.org/10.1097/CM9.0000000000000331
Was this helpful?
0 / 0